BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 17118768)

  • 21. Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals.
    Prieto A; Garcia-Suarez J; Reyes E; Lapeña P; Hernandez M; Alvarez-Mon M
    Exp Hematol; 1993 Nov; 21(12):1563-9. PubMed ID: 8405237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.
    Dewson G; Snowden RT; Almond JB; Dyer MJ; Cohen GM
    Oncogene; 2003 May; 22(17):2643-54. PubMed ID: 12730678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
    Mengubas K; Riordan FA; Bravery CA; Lewin J; Owens DL; Mehta AB; Hoffbrand AV; Wickremasinghe RG
    Oncogene; 1999 Apr; 18(15):2499-506. PubMed ID: 10229201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of cell survival during B lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone marrow of mice with altered expression of IL-7 and recombinase-activating gene-2.
    Lu L; Chaudhury P; Osmond DG
    J Immunol; 1999 Feb; 162(4):1931-40. PubMed ID: 9973461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
    Kusenda J; Babusíková O
    Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.
    Rutella S; Rumi C; Puggioni P; Barberi T; Di Mario A; Larocca LM; Leone G
    Haematologica; 1999 May; 84(5):419-24. PubMed ID: 10329920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells.
    Poggi A; Prevosto C; Catellani S; Rocco I; Garuti A; Zocchi MR
    Br J Haematol; 2010 Nov; 151(3):252-64. PubMed ID: 20813004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
    De Fanis U; Romano C; Dalla Mora L; Sellitto A; Guastafierro S; Tirelli A; Bresciano E; Giunta R; Lucivero G
    Oncol Rep; 2003; 10(3):653-8. PubMed ID: 12684639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
    Hu C; Xiong J; Zhang L; Huang B; Zhang Q; Li Q; Yang M; Wu Y; Wu Q; Shen Q; Gao Q; Zhang K; Sun Z; Liu J; Jin Y; Tan J
    Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estradiol increases the Bax/Bcl-2 ratio and induces apoptosis in the anterior pituitary gland.
    Zaldivar V; Magri ML; Zárate S; Jaita G; Eijo G; Radl D; Ferraris J; Pisera D; Seilicovich A
    Neuroendocrinology; 2009; 90(3):292-300. PubMed ID: 19684383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Apoptosis in chronic lymphocytic leukemia].
    Giordano M
    Medicina (B Aires); 2000; 60 Suppl 2():12-6. PubMed ID: 11188924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis.
    Büssing A; Stein GM; Stumpf C; Schietzel M
    Anticancer Res; 1999; 19(5B):3953-9. PubMed ID: 10628337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
    Kobylinska A; Blonski JZ; Hanausek M; Walaszek Z; Robak T; Kilianska ZM
    Oncol Rep; 2004 Mar; 11(3):699-705. PubMed ID: 14767525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of the Bcl-2 and Bax isoforms in CD19 positive B-lymphocytes isolated from patients diagnosed with chronic lymphocytic leukaemia.
    Ghassemifar R; Forster L; Finlayson J; Calogero T; Augustson B; Joske D; Cull G
    Pathology; 2012 Dec; 44(7):632-7. PubMed ID: 23172082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct or reverse correlations within the expression of activation, differentiation or T-B cooperation molecules on chronic lymphocytic leukemia B cells.
    Sellitto A; De Fanis U; Romano C; Dalla Mora L; Guastafierro S; Tirelli A; Lucivero G
    Minerva Med; 2003 Oct; 94(5):331-6, 336-9. PubMed ID: 14973427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
    de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
    J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Fas and Bcl-2 expression on peripheral blood T and B lymphocytes from juvenile-onset systemic lupus erythematosus, but not from juvenile rheumatoid arthritis and juvenile dermatomyositis.
    Liphaus BL; Kiss MH; Carrasco S; Goldenstein-Schainberg C
    Clin Dev Immunol; 2006; 13(2-4):283-7. PubMed ID: 17162369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
    Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
    J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
    Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.